Overview

Safety of LBH589 Alone and in Combination With Intravenous Docetaxel and Prednisone

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This 2-arm study is designed to determine the maximum tolerated dose of LBH589 as a single agent and in combination with docetaxel and prednisone 5 mg twice daily (second arm) and to characterize the safety, tolerability, biologic activity and pharmacokinetic profile.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Docetaxel
Panobinostat
Prednisone